Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 3Head and Neck Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Erectile Dysfunction 2Carcinoma 2Adenocarcinoma 2Urogenital Neoplasms 1Pyridoxine-dependent epilepsy 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Multiple Myeloma 1Mouth Neoplasms 1Glioblastoma 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Astrocytoma 1Abdominal Cancer 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Tadalafil × Clear all
NCT01374217 2018-12-10

Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated
14 enrolled 8 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡